Light Chain Al Amyloidosis clinical trials

Explore recruiting light chain al amyloidosis clinical trials.

Recruiting light chain al amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Light Chain Al Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Belgium, Denmark, Austria, Netherlands, Germany, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis

Greece, Italy, France, Germany, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis

Germany, Poland, Austria, Italy, Czechia, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Germany, France, Spain, Netherlands, Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis

Spain, Germany, Czechia, Poland, Greece, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Light Chain Al Amyloidosis trials by city

Light Chain Al Amyloidosis in Toronto Light Chain Al Amyloidosis in Vancouver Light Chain Al Amyloidosis in Montreal Light Chain Al Amyloidosis in Calgary Light Chain Al Amyloidosis in Edmonton Light Chain Al Amyloidosis in Ottawa Light Chain Al Amyloidosis in Winnipeg Light Chain Al Amyloidosis in Quebec City Light Chain Al Amyloidosis in Hamilton Light Chain Al Amyloidosis in Kitchener Light Chain Al Amyloidosis in London Light Chain Al Amyloidosis in Halifax Light Chain Al Amyloidosis in New York Light Chain Al Amyloidosis in Los Angeles Light Chain Al Amyloidosis in Chicago Light Chain Al Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease